{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:38:10Z","timestamp":1777970290612,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>We aimed to evaluate the efficacy and safety of eptinezumab for the preventive treatment of chronic migraine in a predominantly Asian population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The multi-regional, randomized, double-blind, placebo-controlled, phase 3 SUNRISE trial randomly assigned adults with chronic migraine to receive eptinezumab 100\u2005mg, 300\u2005mg, or placebo. The primary endpoint was change from baseline in monthly migraine days (MMDs) during Weeks 1\u201312. Key secondary efficacy endpoints were 50% reduction in MMDs (Weeks 1\u201312) and 75% reduction in MMDs (Weeks 1\u20134, Weeks 1\u201312), and the percentage of participants experiencing migraine on Day 1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 978 participants received treatment, including 621 (63.5%) from Asia. Both eptinezumab doses met the primary and all key secondary efficacy endpoints. The mean change from baseline in MMDs (Weeks 1\u201312) was \u22127.2 for eptinezumab 100\u2005mg, \u22127.5 for eptinezumab 300\u2005mg, and \u22124.8 for placebo. Between-group differences were \u22122.4 for eptinezumab 100\u2005mg versus placebo (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and \u22122.7 for eptinezumab 300\u2005mg versus placebo (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Both eptinezumab doses also demonstrated an odds ratio of &gt;2 versus placebo for all migraine responder rates (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and a lower percentage of participants experiencing migraine on Day 1 versus placebo (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009\u2264\u20090.01). Safety outcomes were similar across treatment groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Eptinezumab demonstrated statistically significant greater reductions in MMDs compared with placebo, beginning on Day 1 and sustained through Week 12, with a well-tolerated safety profile consistent with prior clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (Identifier: NCT04921384); EudraCT (Identifier: 2020-001657-42).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024251386095","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:35:57Z","timestamp":1760549757000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial"],"prefix":"10.1177","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-088X","authenticated-orcid":false,"given":"Shengyuan","family":"Yu","sequence":"first","affiliation":[{"name":"The First Medical Center, Chinese PLA General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5852-0146","authenticated-orcid":false,"given":"Yasuhiko","family":"Matsumori","sequence":"additional","affiliation":[{"name":"Sendai Headache and Neurology Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-4682","authenticated-orcid":false,"given":"Byung-Kun","family":"Kim","sequence":"additional","affiliation":[{"name":"Eulji University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4430-1804","authenticated-orcid":false,"given":"Anna","family":"Gryglas-Dworak","sequence":"additional","affiliation":[{"name":"MIGRE Polskie Centrum Leczenia Migreny"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1836-5610","authenticated-orcid":false,"given":"Gvantsa","family":"Giorgadze","sequence":"additional","affiliation":[{"name":"Aversi Clinic LTD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Vall d\u2019Hebron University Hospital, Headache and Neurological Pain Research Group, VHIR, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Krog Josiassen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Ranc","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8926-3012","authenticated-orcid":false,"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lia","family":"Mittoux","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rn","family":"Sperling","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2678-6956","authenticated-orcid":false,"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Tominaga Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0846-2"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207218"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059548"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-024-00690-7"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211024153"},{"key":"e_1_3_3_9_2","article-title":"A literature review of the educational gaps and needs in migraine management: an Asian perspective within a global context","volume":"16","author":"Ching SM","year":"2024","unstructured":"Ching SM, Yong FL, Jao HW, et al. A literature review of the educational gaps and needs in migraine management: an Asian perspective within a global context. Cureus 2024; 16: e75337.","journal-title":"Cureus"},{"key":"e_1_3_3_10_2","article-title":"International headache society global practice recommendations for the acute pharmacological treatment of migraine","volume":"44","author":"Puledda F","year":"2024","unstructured":"Puledda F, Sacco S, Diener HC, et al. International headache society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 2024; 44: 3331024241252666.","journal-title":"Cephalalgia"},{"key":"e_1_3_3_11_2","article-title":"International headache society global practice recommendations for preventive pharmacological treatment of migraine","volume":"44","author":"Puledda F","year":"2024","unstructured":"Puledda F, Sacco S, Diener HC, et al. International headache society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia 2024; 44: 3331024241269735.","journal-title":"Cephalalgia"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1971179"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1222912"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01775-6"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.264671"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2004.05.067"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00310.x"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03477-z"},{"key":"e_1_3_3_21_2","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy W","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD, USA: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14120"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14295"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01514-9"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01186-3"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419858355"},{"key":"e_1_3_3_28_2","volume-title":"VYEPTI [package insert]","year":"2025","unstructured":"VYEPTI [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc., 2025."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01555.x"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14737"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02123-w"},{"key":"e_1_3_3_32_2","first-page":"82","article-title":"Efficacy and safety of eptinezumab for migraine: a systematic review and meta-analysis","volume":"28","author":"Zhong Y","year":"2023","unstructured":"Zhong Y, Wang J, Li H, et al. Efficacy and safety of eptinezumab for migraine: a systematic review and meta-analysis. J Res Med Sci 2023; 28: 82.","journal-title":"J Res Med Sci"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251386095","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024251386095","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251386095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:35Z","timestamp":1777387595000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024251386095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/03331024251386095"],"URL":"https:\/\/doi.org\/10.1177\/03331024251386095","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"03331024251386095"}}